Axil Capital's Past News
DT Axis added to our portfolio companies.
LinqMed added to our portfolio companies.
Portfolio Companies' Past News
LinqMed has demonstrated the efficacy of a “hypoxia-targeted” localized radiotherapy for malignant brain tumors.
An article by Cranebio’s CTO has been published in the intellectual property journal ‘Patent’
Y4.com has obtained a patent for an AI-driven ‘real-time health incentives’ system based on personal health records.
Eurus Therapeutics and Perseus Proteomics have signed a partnership agreement to develop new drugs by leveraging synergies between genome-editing technologies and antibody libraries.
LinqMed has completed construction of its radiopharmaceutical manufacturing plant.
Abrax Japan is renewing its collaborative research with Kyushu University and advancing optimization studies of the new compound AJ04.
DT-Axis has initiated a joint R&D program with academic partners to develop a treatment app for perinatal depression.
The CTO of GEXVal gave a presentation at the Japanese Society for Bioinformatics.
Medtronic Partners with Techsomed on AI-Powered Ablation Therapy.
United Immunity has been selected for Nakanoshima Qross's 'Overseas Ecosystem Bridge Support' program.
MabGenesis and Nippon Soda announce collaboration to discover and develop novel monoclonal antibodies for canine and feline use.
Jolly Good has demonstrated the effectiveness of dementia care education using VR in a collaborative study with George Mason University.
Cranebio has completed its Series B funding.
Y4.com reported its ICT services have had a significant effect on reducing medical costs and improving the health of its customers.
Pulmotect initiates Phase II Clinical Trial in immunosuppressed cancer patients.
An interview with Ms. Yukie Yoshii, CEO of LinqMed, has been published in JST News by the Japan Science and Technology Agency.
United Immunity presented its P-LNP technology at the Annual Meeting of Nucleic Acids Therapeutics Society of Japan.
Abrax Japan showcases breakthrough topical therapeutics at BIO International 2025.
MabGenesis has signed a collaborative research agreement with Ceva Santé Animale S.A.
MabGenesis reaches a milestone in collaboration with Kyoritsu Pharmaceutical.
Y4.com will hold its service event of personal health record at the Osaka Kansai Expo.
With the cooperation of Jolly Good, a paper on "Neurosurgery Education" was published in an international medical journal.
Dr. Kanbayashi, co-founder of Abrax Japan, will be speaking at Yale Innovation Summit 2025.
Virbac licenses MabGenesis’ therapeutic antibodies for canine diseases.
CynosBio has started Phase III Clinical Trial of "IK-01" for osteoarthritis of the knee.
GEXVal Receives Funding from a Parkinson’s Research Program at The Michael J. Fox Foundation.
MabGenesis announces collaboration with MSD Animal Health to discover and develop novel monoclonal antibodies for use in companion animals.
Hirosaki LI has changed its name to CynosBio.
Techsomed reported the evaluation of its imaging analysis software for ablation in an online journal.
LinqMed has raised a total of 1.5 billion yen in funding during the Series B round (first close).
Elixiron reported the results of the Phase 1 clinical study of EL-1071 in the Journal of the Alzheimer's Association.
GEXVal and FRAXA, a U.S. patient advocacy group, collaborate on a Phase 2 clinical study for Fragile X syndrome.
© Axil Capital All Rights Reserved
